90 related articles for article (PubMed ID: 21523722)
41. Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
Kim JH; Yoon YS; Kim JC; Kim YM
Anticancer Res; 2019 Jan; 39(1):313-318. PubMed ID: 30591474
[TBL] [Abstract][Full Text] [Related]
42. [Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Kajino T; Higuchi M; Hata K; Shibata N
Gan To Kagaku Ryoho; 1996 Jan; 23(1):115-7. PubMed ID: 8546461
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Kim GM; Kim YS; Ae Kang Y; Jeong JH; Kim SM; Hong YK; Sung JH; Lim ST; Kim JH; Kim SK; Cho BC
J Thorac Oncol; 2012 Apr; 7(4):731-6. PubMed ID: 22425922
[TBL] [Abstract][Full Text] [Related]
44. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
45. Chemotherapy for recurrent ovarian cancer.
Kaye SB
Lancet; 2003 Jun; 361(9375):2094-5. PubMed ID: 12826426
[No Abstract] [Full Text] [Related]
46. [Treatment of platinum-resistant ovarian cancer].
Onishi Y; Nakamura T; Hatae M
Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
[No Abstract] [Full Text] [Related]
47. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
Kim HS; Park SY; Park CY; Kim YT; Kim BJ; Song YJ; Kim BG; Kim YB; Cho CH; Kim JH; Song YS
Br J Cancer; 2021 Jan; 124(2):375-382. PubMed ID: 32994466
[TBL] [Abstract][Full Text] [Related]
48. Carbon beam therapy in recurrent ovarian cancer.
Nawa A; Suzuki K; Kato S; Fujiwara S; Kajiyama H; Shibata K; Ino K; Nakamura S; Kikkawa F
Ann Oncol; 2008 Jan; 19(1):192-4. PubMed ID: 18084046
[No Abstract] [Full Text] [Related]
49. [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
Shitara K; Munakata M; Ishiguro A; Kudo T; Okada R; Tomioka R; Mitobe S; Yokoyama S; Sakata Y
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1497-1500. PubMed ID: 17033246
[TBL] [Abstract][Full Text] [Related]
50. Hycamtin achieves promising results in study of patients with leukemia.
Oncology (Williston Park); 1996 Dec; 10(12):1860. PubMed ID: 8985969
[No Abstract] [Full Text] [Related]
51. Early versus delayed treatment of relapsed ovarian cancer.
Rustin G; van der Burg M; Griffin C; Qian W; Swart AM
Lancet; 2011 Jan; 377(9763):380-1. PubMed ID: 21277438
[No Abstract] [Full Text] [Related]
52. Trial of topotecan as first-line treatment for ovarian cancer announced.
Oncology (Williston Park); 1996 Mar; 10(3):416. PubMed ID: 8820452
[No Abstract] [Full Text] [Related]
53. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1991 Jun; 18(3):222-32. PubMed ID: 2042062
[No Abstract] [Full Text] [Related]
54. Clinical studies of topotecan.
Broom C
Ann N Y Acad Sci; 1996 Dec; 803():264-71. PubMed ID: 8993520
[No Abstract] [Full Text] [Related]
55. Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases.
Tanaka T; Umesaki N; Ogita S
Eur J Gynaecol Oncol; 2000; 21(4):377-9. PubMed ID: 11055487
[TBL] [Abstract][Full Text] [Related]
56. Phase I clinical trial of recombinant human interleukin-3 combined with carboplatin in the treatment of patients with recurrent ovarian carcinoma.
Rusthoven JJ; Eisenhauer E; Mazurka J; Hirte H; O'Connell G; Muldal A; Lu HX; Onetto N; Swenerton K; Jeffrey J
J Natl Cancer Inst; 1993 May; 85(10):823-5. PubMed ID: 8487328
[No Abstract] [Full Text] [Related]
57. Chemotherapy in advanced ovarian cancer.
Stewart LA; Guthrie D; Parmar MK; Williams CJ
BMJ; 1992 Jan; 304(6819):119. PubMed ID: 1531311
[No Abstract] [Full Text] [Related]
58. Gynaecological cancer: AURELIA--ovarian combination.
Errico A
Nat Rev Clin Oncol; 2014 May; 11(5):242. PubMed ID: 24687034
[No Abstract] [Full Text] [Related]
59. Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration.
Giovannoni S; Trenta P
J Gynecol Oncol; 2014 Oct; 25(4):355-6. PubMed ID: 25310036
[No Abstract] [Full Text] [Related]
60. Reply to F. Tomao et al.
Pujade-Lauraine E; Hilpert F; Poveda A
J Clin Oncol; 2014 Nov; 32(31):3580. PubMed ID: 25185088
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
